What is Harmony Biosciences Holdings, Inc.'s D&A?

Harmony Biosciences Holdings, Inc. (HRMY) reported D&A of $7K in Q1 2026.

How has Harmony Biosciences Holdings, Inc.'s D&A changed year-over-year?

Harmony Biosciences Holdings, Inc.'s D&A decreased by 0.0% year-over-year, from $7K to $7K.

What is the long-term trend for Harmony Biosciences Holdings, Inc.'s D&A?

Over 3 years (2021 to 2024), Harmony Biosciences Holdings, Inc.'s D&A has grown at a -13.7% compound annual growth rate (CAGR), from $416K to $267K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Harmony Biosciences Holdings, Inc. HRMY D&A

D&A at other companies

Jazz PharmaceuticalsJAZZ

$9.1M-12.5%

AlkermesALKS

$19.43M+162%

Axsome TherapeuticsAXSM

$116K-22.1%

Stoke Therapeutics, Inc.STOK

$439K-8.0%

Acadia PharmaceuticalsACAD

$271K+18.3%

Catalyst PharmaceuticalCPRX

$70K-39.1%

Segments

By segment

See full

Rare Neurological Diseases$5.97M0.0%

Other financials

Income statement

See full

Revenue$215.4M+16.6%

Gross profit$170.9M+11.9%

Operating income$37.3M-33.7%

Net income$32.5M-28.7%

EPS (diluted)$0.55-29.5%

Balance sheet

See full

Cash & equivalents$589.4M+20.5%

Total debt$164.6M-7.2%

Total equity$910.3M+26.3%

Total assets$1.3B+20.5%

Cash flow

See full

Operating cash flow$27.8M-18.3%

CapEx$107.0K-79.1%

Free cash flow$126.0M+67.9%

Valuation

See full

Market cap$1.98B-14.9%

Enterprise value$1.55B-24.9%

P/E13.6×-1.6×

P/S2.2×-0.9×

Profitability

See full

Gross margin76.5%-1.8pp

Operating margin21.1%-5.1pp

Net margin16.2%-4.3pp

FCF margin40.1%+9.5pp

Returns & leverage

See full

Return on equity17.9%-6.9pp

Debt / equity0.2×-0.1×

Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s D&A?: Harmony Biosciences Holdings, Inc. (HRMY) reported D&A of $7K in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s D&A changed year-over-year?: Harmony Biosciences Holdings, Inc.'s D&A decreased by 0.0% year-over-year, from $7K to $7K.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s D&A?: Over 3 years (2021 to 2024), Harmony Biosciences Holdings, Inc.'s D&A has grown at a -13.7% compound annual growth rate (CAGR), from $416K to $267K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.